Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises XVIVO in connection with a directed share issue of MSEK 250
Mandate

Vinge advises XVIVO in connection with a directed share issue of MSEK 250

November 01, 2021 Capital Markets and Public M&A

Vinge has advised XVIVO Perfusion AB in connection with a directed new issue of shares to Swedish and international investors that contributed MSEK 250 to XVIVO.

The subscription price of SEK 335, which corresponded to the closing price on Nasdaq Stockholm, was determined through an accelerated book-building procedure arranged by Carnegie and Bryan, Garnier & Co. The proceeds will be used for the financing of XVIVO’s acquisition of Star Teams Inc. which was published on the same day as the directed share issue.

Vinge’s team primarily consisted of Anders Strid, Edin Agic and Anna Ståhlklo.

 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

 Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025